Hi David,
On Fri, Sep 13, 2013 at 9:18 AM, David Corry <dcorry10@nc.rr.com> wrote:
Mr. Ehrlich,
Hope you and family are well and hope you have a relaxing week-end after a very busy summer. I listened to your presentation via the R & R link and felt you did an outstanding job given the time restraints. I’m excited about the acquisition and fundamentally understand the significance. I’m ELATED about the P21 activation. I know you indicated you would be providing a PR in the near future. That will be very much welcomed and appreciated by all of us investors. While I have never questioned the execution of your and Dr. Menons’ plan for Cellceutix, ( I believe it has been BRILLIANT ) there are concerns that me and many fellow investors that listened to the presentation have ….NOT troubling in the long run but more in the short term. So with that in mind, in your PR would you please consider and address these primary concerns. I believe addressing these will elicit a much better reaction than what the market has provided to date post the presentation. Thanks in advance for your response.
1. The P trial that was to start very soon was considered a Short Term Catalyst that would provide reinforcement, creditability and $$$$ ( helping in the UPlist ) …now many believe there will be a serious news GAP could affect shareholder value.
The process for the FDA application is in progress. This will be explained in a PR. I dont expect any "serious news gaps" as we plan to have multiple trials shortly.
2. While the more advanced trials are encouraging, the fear is time and dilution. I understand NO reverse split ( I applauded in my hotel room : ) but can you share some of your thoughts re: BOTH
Management holds many shares so personally we have the same concerns about dilution. It is too early to speculate on this but I expect the markets to understand the value of the acquisition and at the right time do a favorable financing.
3. The P21 at low dosage is Mind Boggling and yet seemed to be minimalized ( I clearly understand that duplication of tests is necessary given significance ) ….WILL or even CAN you elaborate on this ?
Exactly that. We need more confirmation with more samples.
4. The advanced trials will require more $$$ than the POC ….will that ultimately impact and delay UPlisting ? Thoughts on where the $$$ come from? Another Aspire type deal ?
Absolutely a similar type financing is an excellent option for Cellceutix. The shares have no fixed price. As the Company executes it sells shares at higher prices. (There are other excellent options as well.)
Thanks again Mr. Ehrlich and if you do choose to respond, I would like to share same on the Investor Hangout and iHUB board. TGIF !
Regards,
